ADPriboDB: A database of ADP-ribosylated proteins

Case ID:
Disclosure Date:
Unmet Need
Pharmaceutical companies are conducting clinical trials for PARP inhibitors to treat cancer patients.  There is currently only one drug approved in this class, but there is a need for continued and improved knowledge of PARP substrates. 

Technology Overview
JHU researchers created a database that curates the last 30 years of literature on ADP-ribosylation and over 5000 substrates in humans, mouse and rate as well as other organisms.  The information can provide additional support and guidance to pharmaceutical companies working in this space.
Stage of Development
The database is available at:

Please contact JHTV for commercial use.
Patent Information:
For Information, Contact:
Seth Zonies
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum